Therefore, a hypothesis is currently proposed that naringenin acts through a series of genes (ESR1, PIK3CA, AKT1, MAPK1, and AR) to control prostate cancer cell proliferation. This evidence concerns the gene PIK3CA and prostate carcinoma.